238 related articles for article (PubMed ID: 23300655)
1. RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry study.
Le Calvez-Kelm F; Oliver J; Damiola F; Forey N; Robinot N; Durand G; Voegele C; Vallée MP; Byrnes G; Registry BC; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV; Lesueur F
PLoS One; 2012; 7(12):e52374. PubMed ID: 23300655
[TBL] [Abstract][Full Text] [Related]
2. Germline mutation in the RAD51B gene confers predisposition to breast cancer.
Golmard L; Caux-Moncoutier V; Davy G; Al Ageeli E; Poirot B; Tirapo C; Michaux D; Barbaroux C; d'Enghien CD; Nicolas A; Castéra L; Sastre-Garau X; Stern MH; Houdayer C; Stoppa-Lyonnet D
BMC Cancer; 2013 Oct; 13():484. PubMed ID: 24139550
[TBL] [Abstract][Full Text] [Related]
3. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study.
Damiola F; Pertesi M; Oliver J; Le Calvez-Kelm F; Voegele C; Young EL; Robinot N; Forey N; Durand G; Vallée MP; Tao K; Roane TC; Williams GJ; Hopper JL; Southey MC; Andrulis IL; John EM; Goldgar DE; Lesueur F; Tavtigian SV
Breast Cancer Res; 2014 Jun; 16(3):R58. PubMed ID: 24894818
[TBL] [Abstract][Full Text] [Related]
4. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
5. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
6. Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.
Golmard L; Castéra L; Krieger S; Moncoutier V; Abidallah K; Tenreiro H; Laugé A; Tarabeux J; Millot GA; Nicolas A; Laé M; Abadie C; Berthet P; Polycarpe F; Frébourg T; Elan C; de Pauw A; Gauthier-Villars M; Buecher B; Stern MH; Stoppa-Lyonnet D; Vaur D; Houdayer C
Eur J Hum Genet; 2017 Dec; 25(12):1345-1353. PubMed ID: 29255180
[TBL] [Abstract][Full Text] [Related]
7. RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families.
Pelttari LM; Kiiski JI; Ranta S; Vilske S; Blomqvist C; Aittomäki K; Nevanlinna H
Springerplus; 2015; 4():92. PubMed ID: 25918678
[TBL] [Abstract][Full Text] [Related]
8. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study.
Le Calvez-Kelm F; Lesueur F; Damiola F; Vallée M; Voegele C; Babikyan D; Durand G; Forey N; McKay-Chopin S; Robinot N; Nguyen-Dumont T; Thomas A; Byrnes GB; ; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV
Breast Cancer Res; 2011 Jan; 13(1):R6. PubMed ID: 21244692
[TBL] [Abstract][Full Text] [Related]
9. Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk.
Ricks-Santi LJ; Sucheston LE; Yang Y; Freudenheim JL; Isaacs CJ; Schwartz MD; Dumitrescu RG; Marian C; Nie J; Vito D; Edge SB; Shields PG
BMC Cancer; 2011 Jun; 11():278. PubMed ID: 21708019
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer risk and common single nucleotide polymorphisms in homologous recombination DNA repair pathway genes XRCC2, XRCC3, NBS1 and RAD51.
Silva SN; Tomar M; Paulo C; Gomes BC; Azevedo AP; Teixeira V; Pina JE; Rueff J; Gaspar JF
Cancer Epidemiol; 2010 Feb; 34(1):85-92. PubMed ID: 20004634
[TBL] [Abstract][Full Text] [Related]
11. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
Wong MW; Nordfors C; Mossman D; Pecenpetelovska G; Avery-Kiejda KA; Talseth-Palmer B; Bowden NA; Scott RJ
Breast Cancer Res Treat; 2011 Jun; 127(3):853-9. PubMed ID: 21409391
[TBL] [Abstract][Full Text] [Related]
12. Screening for RAD51 and BRCA2 BRC repeat mutations in breast and ovarian cancer families.
Rapakko K; Heikkinen K; Karppinen SM; Winqvist R
Cancer Lett; 2006 May; 236(1):142-7. PubMed ID: 16005565
[TBL] [Abstract][Full Text] [Related]
13. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
[TBL] [Abstract][Full Text] [Related]
14. Variation in the RAD51 gene and familial breast cancer.
Lose F; Lovelock P; Chenevix-Trench G; Mann GJ; Pupo GM; Spurdle AB;
Breast Cancer Res; 2006; 8(3):R26. PubMed ID: 16762046
[TBL] [Abstract][Full Text] [Related]
15. Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families.
Johnson J; Healey S; Khanna KK; ; Chenevix-Trench G
Breast Cancer Res Treat; 2011 Aug; 129(1):255-63. PubMed ID: 21533530
[TBL] [Abstract][Full Text] [Related]
16. Combined effect of polymorphisms in Rad51 and Xrcc3 on breast cancer risk and chromosomal radiosensitivity.
Vral A; Willems P; Claes K; Poppe B; Perletti G; Thierens H
Mol Med Rep; 2011; 4(5):901-12. PubMed ID: 21725594
[TBL] [Abstract][Full Text] [Related]
17. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiñski J; Scott RJ; Hamann U
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):270-5. PubMed ID: 17301259
[TBL] [Abstract][Full Text] [Related]
18. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA
BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725
[TBL] [Abstract][Full Text] [Related]
19. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.
; Dorling L; Carvalho S; Allen J; González-Neira A; Luccarini C; Wahlström C; Pooley KA; Parsons MT; Fortuno C; Wang Q; Bolla MK; Dennis J; Keeman R; Alonso MR; Álvarez N; Herraez B; Fernandez V; Núñez-Torres R; Osorio A; Valcich J; Li M; Törngren T; Harrington PA; Baynes C; Conroy DM; Decker B; Fachal L; Mavaddat N; Ahearn T; Aittomäki K; Antonenkova NN; Arnold N; Arveux P; Ausems MGEM; Auvinen P; Becher H; Beckmann MW; Behrens S; Bermisheva M; Białkowska K; Blomqvist C; Bogdanova NV; Bogdanova-Markov N; Bojesen SE; Bonanni B; Børresen-Dale AL; Brauch H; Bremer M; Briceno I; Brüning T; Burwinkel B; Cameron DA; Camp NJ; Campbell A; Carracedo A; Castelao JE; Cessna MH; Chanock SJ; Christiansen H; Collée JM; Cordina-Duverger E; Cornelissen S; Czene K; Dörk T; Ekici AB; Engel C; Eriksson M; Fasching PA; Figueroa J; Flyger H; Försti A; Gabrielson M; Gago-Dominguez M; Georgoulias V; Gil F; Giles GG; Glendon G; Garcia EBG; Alnæs GIG; Guénel P; Hadjisavvas A; Haeberle L; Hahnen E; Hall P; Hamann U; Harkness EF; Hartikainen JM; Hartman M; He W; Heemskerk-Gerritsen BAM; Hillemanns P; Hogervorst FBL; Hollestelle A; Ho WK; Hooning MJ; Howell A; Humphreys K; Idris F; Jakubowska A; Jung A; Kapoor PM; Kerin MJ; Khusnutdinova E; Kim SW; Ko YD; Kosma VM; Kristensen VN; Kyriacou K; Lakeman IMM; Lee JW; Lee MH; Li J; Lindblom A; Lo WY; Loizidou MA; Lophatananon A; Lubiński J; MacInnis RJ; Madsen MJ; Mannermaa A; Manoochehri M; Manoukian S; Margolin S; Martinez ME; Maurer T; Mavroudis D; McLean C; Meindl A; Mensenkamp AR; Michailidou K; Miller N; Mohd Taib NA; Muir K; Mulligan AM; Nevanlinna H; Newman WG; Nordestgaard BG; Ng PS; Oosterwijk JC; Park SK; Park-Simon TW; Perez JIA; Peterlongo P; Porteous DJ; Prajzendanc K; Prokofyeva D; Radice P; Rashid MU; Rhenius V; Rookus MA; Rüdiger T; Saloustros E; Sawyer EJ; Schmutzler RK; Schneeweiss A; Schürmann P; Shah M; Sohn C; Southey MC; Surowy H; Suvanto M; Thanasitthichai S; Tomlinson I; Torres D; Truong T; Tzardi M; Valova Y; van Asperen CJ; Van Dam RM; van den Ouweland AMW; van der Kolk LE; van Veen EM; Wendt C; Williams JA; Yang XR; Yoon SY; Zamora MP; Evans DG; de la Hoya M; Simard J; Antoniou AC; Borg Å; Andrulis IL; Chang-Claude J; García-Closas M; Chenevix-Trench G; Milne RL; Pharoah PDP; Schmidt MK; Spurdle AB; Vreeswijk MPG; Benitez J; Dunning AM; Kvist A; Teo SH; Devilee P; Easton DF
N Engl J Med; 2021 Feb; 384(5):428-439. PubMed ID: 33471991
[TBL] [Abstract][Full Text] [Related]
20. RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.
Clague J; Wilhoite G; Adamson A; Bailis A; Weitzel JN; Neuhausen SL
PLoS One; 2011; 6(9):e25632. PubMed ID: 21980511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
